MedTrace Logo

Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases

NCT04411290 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-06-02

No results posted yet for this study

Summary

In the last decades, thyroid cancer incidence has continuously increased all over the world, almost exclusively due to a sharp rise in the incidence of the papillary histologic subtype, which has the highest incidence of multifocality. Furthermore, Black Sea and Eastern European regions are both endemic and known to have been under the influence of Chernobyl nuclear explosion. Although overscreening might have a role in certain parts of the world, the predictors of malignancy such as family history, genetical disorders, previous radiation exposure, low iodine intake, diabetes and obesity, should also be taken into consideration in determining the extent of surgery.

Conditions

  • Thyroid Carcinoma
  • Thyroid Papillary Carcinoma
  • Multinodular Goiter, Adolescent
  • Solitary Thyroid Nodule
  • Thyroid Diseases
  • Multifocal Dysplasia
  • Aspiration
  • Thyroid Nodule
  • Thyroid Cancer, Papillary
  • Thyroid Neoplasms
  • Thyroid Goiter

Interventions

PROCEDURE

Total thyroidectomy (TT)

Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)

Sponsors & Collaborators

  • Umraniye Education and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Ethem UNAL, MD, PhD · Assoc. Professor of General Surgery and Surgical Oncology

  • Sema YUKSEKDAG, MD · Instructor in General Surgery

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411290 on ClinicalTrials.gov